Normal range of calcitonin in children measured by a chemiluminescent two-site immunometric assay

Hormone Research

Volumn 66, Issue 1, 2006, Pages 17-20

  Verga, Uberta ^a   Morpurgo, Paola S ^a   Vaghi, Ivan ^a   Radetti, Giorgio ^b   Beck Peccoz, Paolo ^a,c  

^a UNIVERSITY OF MILAN   (Italy)

^b CENTRAL HOSPITAL OF BOLZANO   (Italy)

^c Institute of Dermatological Sciences   (Italy)

Author keywords

C cell hyperplasia; Calcitonin; Children; Immunometric assay; Medullary thyroid carcinoma

Indexed keywords

CALCITONIN;

ADOLESCENT; ADULT; AGE; ARTICLE; CALCITONIN BLOOD LEVEL; CHEMILUMINESCENT TWO SITE IMMUNOMETRIC ASSAY; CHEMOLUMINESCENCE; CHILD; CONTROLLED STUDY; CORRELATION FUNCTION; FEMALE; HORMONE DETERMINATION; HUMAN; IMMUNOASSAY; MALE; NORMAL HUMAN; NORMAL VALUE; PRIORITY JOURNAL; SEX DIFFERENCE;

ADOLESCENT; ADULT; AGING; CALCITONIN; CHEMILUMINESCENT MEASUREMENTS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOASSAY; INFANT; MALE; REFERENCE VALUES; SEX CHARACTERISTICS;

EID: 33745445205     PISSN: 03010163     EISSN: None     Source Type: Journal    
DOI: 10.1159/000092848     Document Type: Article

References (15)

1. Body JJ, Heat H: Estimates of circulating monomeric calcitonin: physiological studies in normal and thyroidectomized man. J Clin Endocrinol Metab 1983;57:897-903
2. Guyetant S, Rousselet MC, Durigon M, Chappard D, Franc B, Guerin O, Saint André JP: Sex-related C-cell hyperplasia in the normal human thyroid: a quantitative autopsy study. J Endocrinol Metab 1997;82:42-47.
3. Niccoli P, Wion-Barbot N, Caron P, Henry JF, de Micco C, Saint André JP, Bigorgne JC, Modigliani E, Conte-Devolx B: Interest of routine measurement of serum calcitonin: study in a large series of thyroidectomized patients. J Clin Endocrinol Metab 1997;82:338-341.
4. LiVolsi VA: C-cell hyperplasia/neoplasia. J Endocrinol Metab 1997;82:39-40.
5. Albores-Saavedra A, Krueger JE: C-cell hyperplasia and medullary thyroid carcinoma. Endocr Pathol 2001;12:365-367.
6. Kotzmann H, Schmidt A, Scheuba C, Kaserer K, Watschinger B, Söregi G, Niederle B, Vierhapper H: Basal calcitonin levels and the response to pentagastrin stimulation in patients after kidney transplantation or on chronic hemodialysis as indicators of medullary carcinoma. Thyroid 1999;9:943-947.
7. Horvit PK, Gagel RF: The goitrus patients with an elevated serum calcitonin. What to do? J Clin Endocrinol Metab 1997;82:335-337.
8. Scheuba C, Kaserer K, Bieglmayer C, Niederle B, Vierhapper H: Prevalence of C-cell hyperplasia in patients with normal basal and pentagastrin-stimulated calcitonin. Thyroid 2000;10:413-416.
9. Marsh D, McDowall D, Hyland V, Andrew S, Schnitzler M, Gaskin E, Nevell D, Diamond T, Delbridge L, Clifton-Bligh P, Robinson B: The identification of false positive responses to the pentagastrin stimulation test in RET mutation negative members of MEN 2A families. Clin Endocrinol 1996;44:213-220.
10. Landsvater RM, Rombouts AG, te Meerman G, Schillorn-van Vee Berends MJ, Geerdink RA, Struyvenberg A, Buys CH, Lips C: The clinical implication of a positive calcitonin test for C-cell hyperplasia in genetically unaffected members of a MEN 2 kindred. Am J Hum Genet 1993;52:335-342.
11. Engelbach M, Görges R, Forst T, Pfützner A, Dawood R, Heerdt S, Kunt T, Bockisch A: Improved diagnostic methods in the follow-up of medullary thyroid carcinoma by highly specific calcitonin measurements. J Clin Endocrinol Metab 2000;85:1890-1894.
12. Skinner MA, Moley JA, Dilley WG, Ozwar K, DeBenedetti MK, Wells SA Jr: Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. N Engl J Med 2005;353:1105-1113.
13. Grauer A, Raue F, Ziegler R: Clinical usefulness of a new chemiluminescent two-site immunoassay for human calcitonin. Exp Clin Endocrinol Diabetes 1998;106:353-356.
14. Perry A, Molberg K, Albores-Saavedra J: Physiologic versus neoplastic C-cell hyperplasia of the thyroid. Cancer 1996;77:750-756.
15. Koch CA, Sarlis NJ: The spectrum of thyroid diseases in childhood and its evolution during transition to adulthood: natural history, diagnosis, differential diagnosis and management. J Endocrinol Invest 2001;24:659-675.